Viatris (VTRS) Other financing activities (2020 - 2026)
Viatris (VTRS) posted quarterly Other financing activities of -$300000.0 for Q1 2026, up 99.73% year-over-year from -$150205.6 in Q1 2025, and up 97.5% quarter-over-quarter from -$12.0 million in Q4 2025.
Viatris (VTRS) Other financing activities (2020 - 2026) Analysis & Trends
Viatris' Other financing activities history runs 7 years deep, the most recent figure standing at -$300000.0 for Q1 2026.
- In Q1 2026, Other financing activities rose 99.73% year-over-year to -$300000.0; the TTM figure through Mar 2026 stood at -$80.8 million (down 145.04% YoY), while the FY2025 annual figure was -$190.1 million, down 164.4% from the prior year.
- Other financing activities for Q1 2026 stood at -$300000.0, up from -$12.0 million in the prior quarter.
- The five-year high for Other financing activities was $290.4 million in Q4 2024, with the low at -$277.2 million in Q4 2023.
- The 5-year median for Other financing activities is $3.0 million (2022), against an average of -$3.1 million.
- The sharpest annual moves came in 2023 and 2025: Other financing activities jumped 17925.0% in 2023, then sank 1867.74% in 2025.
- Viatris' Other financing activities stood at $19.2 million in 2022, then tumbled by 1543.75% to -$277.2 million in 2023, then soared by 204.76% to $290.4 million in 2024, then slumped by 104.13% to -$12.0 million in 2025, then surged by 97.5% to -$300000.0 in 2026.
- Business Quant data shows VTRS's Other financing activities at -$300000.0 in Q1 2026, -$12.0 million in Q4 2025, and -$179.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.50 Mn |
| Jun 30, 2026 | -24.50 Mn |
| Mar 31, 2026 | -300,000.00 |
| Mar 31, 2026 | -300,000.00 |
| Dec 31, 2025 | -12.00 Mn |
| Dec 31, 2025 | -12.00 Mn |
| Sep 30, 2025 | -179.10 Mn |
| Sep 30, 2025 | -179.10 Mn |
| Jun 30, 2025 | 110.60 Mn |
| Jun 30, 2025 | 110.60 Mn |
| Mar 31, 2025 | -109.60 Mn |
| Mar 31, 2025 | -109.60 Mn |
| Dec 31, 2024 | 290.40 Mn |
| Dec 31, 2024 | 290.40 Mn |
| Sep 30, 2024 | -124.00 Mn |
| Sep 30, 2024 | -124.00 Mn |
| Jun 30, 2024 | 122.60 Mn |
| Jun 30, 2024 | 122.60 Mn |
| Mar 31, 2024 | 6.20 Mn |
| Mar 31, 2024 | 6.20 Mn |